Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 4
2004 5
2005 5
2006 6
2007 2
2008 10
2009 10
2010 7
2011 10
2012 9
2013 8
2014 10
2015 17
2016 24
2017 21
2018 19
2019 21
2020 28
2021 31
2022 55
2023 32
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Su YW, Qiu YZ, Wang YH, Xu Y, Huang CC, Zhang Q, Su C, Ma JH, Liu W, Liu Y, Zhao MS, Yang HY, Li CL, Lu X. Su YW, et al. Vaccine. 2024 Apr 2;42(9):2438-2447. doi: 10.1016/j.vaccine.2024.03.005. Epub 2024 Mar 8. Vaccine. 2024. PMID: 38461050 Clinical Trial.
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F, Qiu Y, Wu Z, Wang YH, Cai C, Fu L, Jiao W, Wang H, Gao M, Su C, Ma JH, Xu Y, Huang CC, Zhang Q, Ni S, Zhao M, Guo L, Ji L, Yang H, Zhao Y, Li C, Lu X, Su YW, Li Q. Jin F, et al. Among authors: li c. Vaccine. 2024 Mar 7;42(7):1561-1570. doi: 10.1016/j.vaccine.2024.01.098. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38365485 Clinical Trial.
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ. Chen GL, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18. Hum Vaccin Immunother. 2023. PMID: 38111106 Free PMC article. Clinical Trial.
307 results